Pheochromocytomas and paragangliomas in patients with congenital heart defects

The correlation between pheochromocytoma/paraganglioma (PHEO/PGL) and cyanotic congenital heart defects is rare but not coincidental. Research suggests that the development of PHEO/PGL in these patients maybe explained by chronic hypoxia, disruptions in the sympathetic nervous system, and potential genetic predisposition. These factors may provoke the tumor transformation of chromaffin cells. Additionally, diagnosing PHEO/PGL in patients with heart defects is complicated by hemodynamic disturbances that mask the characteristic sympathoadrenal crises of PHEO/PGL. The occurrence of these neoplasms can exacerbate the clinical course of congenital defects due to increased catecholamine secretion, leading to vasoconstriction and worsening hypoxia. We present two clinical cases of PHEO/PGL in the context of congenital heart defects, with patients observed and treated at the N.N. Blokhin National Medical Research Center of Oncology and the A.N. Bakoulev National Medical Research Center of Cardiovascular Surgery. These observations emphasize the importance of vigilance for symptoms of tachycardia and uncontrolled hypertension in such patients. Despite their rarity, the relationship between these pathologies must be considered for accurate diagnosis and optimal treatment selection.

1. Manger WM. The Protean Manifestations of Pheochromocytoma. Horm Metab Res. 2009;41(09):658–663. doi: https://doi.org/10.1055/s-0028-1128139

2. Else T, Greenberg S, Fishbein L. Hereditary Paraganglioma Pheochromocytoma Syndromes. 2008 May 21 [updated 2023 Sep 21]. In: Adam MP, Feldman J, Mirzaa GM, Pagon RA, Wallace SE, Amemiya A, editors. GeneReviews® [Internet]. Seattle (WA): University of Washington, Seattle; 1993–2024

3. Folger GM, Jr, Roberts WC, Mehrizi A, Shah KD, Glancy DL, Carpenter CC, et al. Cyanotic malformations of the heart with pheochromocytoma. A report of five cases. Circulation. 1964;29:750–7. doi: https://doi.org/10.1161/01.CIR.29.5.750

4. Gruber H, Metson R. Carotid body paraganglioma regression with relief of hypoxemia. Ann Intern Med. 1980;92(6):800–802

5. Bockelman HW, Arya S, Gilbert EF. Cyanotic congenital heart disease with malignant paraganglioma. Cancer. 1982;50(11):2513-7. doi: https://doi.org/10.1002/1097-0142(19821201)50:11<2513::aid-cncr2820501143>3.0.co;2-6. PMID: 7139543

6. Ng P, Deepak D, Teo L, Low TT. Asymptomatic phaeochromocytoma in a patient with Holt-Oram syndrome: a case report. Eur Heart J Case Rep. 2019;3(4):1-5. doi: https://doi.org/10.1093/ehjcr/ytz206

7. Doyle C, Bolger J, Conneely JB, Walsh KP. Paraganglioma in an adolescent awaiting a cardiac transplant due to unrepaired congenital cyanotic heart disease and a univentricular heart: the first reported case. BMJ Case Rep. 2021;14(5):e241804. doi: https://doi.org/10.1136/bcr-2021-241804

8. Opotowsky AR, Moko LE, Ginns J, Rosenbaum M, Greutmann M, et al. Pheochromocytoma and paraganglioma in cyanotic congenital heart disease. J Clin Endocrinol Metab. 2015;100(4):1325-34. doi: https://doi.org/10.1210/jc.2014-3863

9. Jensterle M, Podbregar A, Janež A, Rakusa M, Goricar K, Prokšelj K. Comparison of plasma metanephrines in patients with cyanotic and acyanotic congenital heart disease. Endocrine. 2022;78(3):580-586. doi: https://doi.org/10.1007/s12020-022-03205-6

10. Zhao B, Zhou Y, Zhao Y, Zhao Y, Wu X, Bi Y, Luo Y, Ji Z, Rong S. Co-Occurrence of Pheochromocytoma-Paraganglioma and Cyanotic Congenital Heart Disease: A Case Report and Literature Review. Front Endocrinol (Lausanne). 2018;9:165. doi: https://doi.org/10.3389/fendo.2018.00165

11. Jochmanová I, Yang C, Zhuang Z, Pacak K. Hypoxia inducible factor signaling in pheochromocytoma: turning the rudder in the right direction. J Natl Cancer Inst. 2013 Sep 4;105(17):1270-83. doi: https://doi.org/10.1093/jnci/djt201. Epub 2013 Aug PMID: 23940289; PMCID: PMC3888279.

12. Fishbein L, Leshchiner I, Walter V, Danilova L, Robertson AG, Johnson AR, et al. Comprehensive molecular characterization of pheochromocytoma and paraganglioma. Cancer Cell. 2017;31(2):181–93. doi: https://doi.org/10.1016/j.ccell.2017.01.001

13. Ogasawara T, Fujii Y, Kakiuchi N, Shiozawa Y, Sakamoto R, et al. Genetic Analysis of Pheochromocytoma and Paraganglioma Complicating Cyanotic Congenital Heart Disease. J Clin Endocrinol Metab. 2022;107(9):2545-2555. doi: https://doi.org/10.1210/clinem/dgac362

14. Saldana MJ, Salem LE, Travezan R. High altitude hypoxia and chemodectomas. Hum Pathol. 1973 Jun;4(2):251-63. doi: 10.1016/s0046-8177(73)80012-7. PMID: 4706179.

15. Gruber H, Metson R. Carotid body paraganglioma regression with relief of hypoxemia. Ann Intern Med. 1980 Jun;92(6):800-2. doi: https://doi.org/10.7326/0003-4819-92-6-800. PMID: 7387023

16. Bigham AW, Lee FS. Human high-altitude adaptation: forward genetics meets the HIF pathway. Genes Dev. 2014;28(20):2189–204. doi: https://doi.org/10.1101/gad. 250167.114

17. Bamforth SD, Braganca J, Eloranta JJ, Murdoch JN, Marques FI, Kranc KR, et al. Cardiac malformations, adrenal agenesis, neural crest defects and exencephaly in mice lacking Cited2, a new Tfap2 co-activator. Nat Genet. 2001;29(4):469–74. doi: https://doi.org/10.1038/ng768

18. Lenders JW, Duh QY, Eisenhofer G, et al. Pheochromocytoma and paraganglioma: an endocrine society clinical practice guideline. J Clin Endocrinol Metab. 2014;99(6):1915–1942

19. Szatko A, Glinicki P, Gietka-Czernel M. Pheochromocytoma/ paraganglioma-associated cardiomyopathy. Front Endocrinol (Lausanne). 2023 Jul 13;14:1204851. doi: https://doi.org/10.3389/fendo.2023.1204851. PMID: 37522121; PMCID: PMC10374018.

20. Wigerup C, Påhlman S, Bexell D. Therapeutic targeting of hypoxia and hypoxia-inducible factors in cancer. Pharmacol Ther. 2016 Aug;164:152-69. doi: https://doi.org/10.1016/j.pharmthera.2016.04.009. Epub 2016 Apr 29. PMID: 27139518.

21. Zhang J, Cao L, Yan L, Jin C, Zhang D. A young patient with heart failure was diagnosed with extra-adrenal paraganglioma: a case report. BMC Cardiovasc Disord. 2022;22(1):574. doi: https://doi.org/10.1186/s12872-022-03026-5

22. ROBERTS XC, MASON DT, AND BRAUN-WALL E. Survival to adulthood in a patient with complete transposition of the great vessels. Including a note on the association of endocrine tumors with heart disease. Ann. Int.Med. 57:834,1962

23. Brickner ME, Hillis LD, Lange RA. Congenital heart disease in adults. Second of two parts. N Engl J Med. 2000;342(5):334-42. doi: https://doi.org/10.1056/NEJM200002033420507. Erratum in: N Engl J Med 2000;342(13):988

24. Ilanchezhian M, Jha A, Pacak K, Del Rivero J. Emerging Treatments for Advanced/Metastatic Pheochromocytoma and Paraganglioma. Curr Treat Options Oncol. 2020;21(11):85. doi: https://doi.org/10.1007/s11864-020-00787-z